Sign In
Buy LGMK
LogicMark Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$2.07 |
| EPS actual | -$1.68 |
| EPS Surprise | 18.84% |
| Revenue estimate | 2.825M |
| Revenue actual | 3.214M |
| Revenue Surprise | 13.77% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$2.46 |
| EPS actual | -$1.96 |
| EPS Surprise | 20.33% |
| Revenue estimate | 2.26M |
| Revenue actual | 3.065M |
| Revenue Surprise | 35.61% |
| Release date | Nov 12, 2025 |
| EPS estimate | - |
| EPS actual | -$2.21 |
| Revenue estimate | - |
| Revenue actual | 2.915M |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0037 |
| EPS Surprise | 87.57% |
| Revenue estimate | 2.722M |
| Revenue actual | 2.853M |
| Revenue Surprise | 4.83% |
Last 4 Quarters for LogicMark
Below you can see how LGMK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $0.0040 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0037 |
| EPS surprise | 87.57% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $0.0036 |
| Aug 07, 2025 | $0.0042 |
| Aug 08, 2025 | $0.0040 |
| Aug 11, 2025 | $0.0045 |
| Aug 12, 2025 | $0.0040 |
| Aug 13, 2025 | $0.0040 |
| Aug 14, 2025 | $0.0042 |
| Aug 15, 2025 | $0.0045 |
| Aug 18, 2025 | $0.0039 |
| 4 days before | 11.11% |
| 4 days after | -2.50% |
| On release day | 0% |
| Change in period | 8.33% |
| Release date | Nov 12, 2025 |
| Price on release | $0.0033 |
| EPS estimate | - |
| EPS actual | -$2.21 |
| Date | Price |
|---|---|
| Nov 06, 2025 | $1.34 |
| Nov 07, 2025 | $1.10 |
| Nov 10, 2025 | $0.0033 |
| Nov 11, 2025 | $0.0033 |
| Nov 12, 2025 | $0.0033 |
| Nov 13, 2025 | $0.0033 |
| Nov 14, 2025 | $0.0033 |
| Nov 17, 2025 | $0.0033 |
| Nov 18, 2025 | $0.0033 |
| 4 days before | -99.75% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -99.75% |
| Release date | Mar 25, 2026 |
| Price on release | $0.455 |
| EPS estimate | -$2.46 |
| EPS actual | -$1.96 |
| EPS surprise | 20.33% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $0.450 |
| Mar 20, 2026 | $0.450 |
| Mar 23, 2026 | $0.605 |
| Mar 24, 2026 | $0.455 |
| Mar 25, 2026 | $0.455 |
| Mar 26, 2026 | $0.455 |
| Mar 27, 2026 | $0.580 |
| Mar 30, 2026 | $0.455 |
| Mar 31, 2026 | $0.536 |
| 4 days before | 1.11% |
| 4 days after | 17.80% |
| On release day | 0% |
| Change in period | 19.11% |
| Release date | May 13, 2026 |
| Price on release | $0.551 |
| EPS estimate | -$2.07 |
| EPS actual | -$1.68 |
| EPS surprise | 18.84% |
| Date | Price |
|---|---|
| May 07, 2026 | $0.504 |
| May 08, 2026 | $0.547 |
| May 11, 2026 | $0.699 |
| May 12, 2026 | $0.504 |
| May 13, 2026 | $0.551 |
| May 14, 2026 | $0.504 |
| May 15, 2026 | $0.679 |
| May 18, 2026 | $0.700 |
| May 19, 2026 | $0.586 |
| 4 days before | 9.27% |
| 4 days after | 6.32% |
| On release day | -8.48% |
| Change in period | 16.17% |
LogicMark Earnings Call Transcript Summary of Q1 2026
Key points for investors:
- Revenue and margins: Q1 2026 revenue was $3.2M, up 24% year-over-year. Gross profit was $2.2M and gross margin expanded to 69.6% (a 610 bps improvement vs. Q1 2025).
- Profitability trajectory: Operating loss narrowed to $1.5M (36% improvement year-over-year) and net loss improved accordingly. Management is focused on disciplined cost management and improving operational leverage.
- Liquidity and balance sheet: Cash and investments were $7.5M at quarter end and the company has no long-term debt. Management states this supports near-term product launches without dilutive financing.
- Product roadmap and commercial catalysts: Two near-term product catalysts — a wearable watch targeted to seniors (planned for Q3 launch) and a connected-home hub progressing through beta with senior/independent living partners. Existing Freedom Alert Max and Aster platforms broaden addressable markets.
- Recurring revenue strategy: Company is transitioning from one-time device sales to subscription tiers, monitored/connected care services, and selective licensing, enabled by a cloud-based, modular platform and an expanding patent portfolio.
- R&D and go-to-market: R&D spend is lower versus prior year as the company moves into commercialization (management cites roughly $100k/month of development spend). Selling and channel investments have increased to scale healthcare, government and B2B distribution.
- Competitive & market context: Management highlights strong demographic tailwinds (aging population, falls as a major safety risk), a high Net Promoter Score (68), and a renewed 5-year GSA contract as durable channel advantages.
- Risks and focus areas: Execution risks around product launches, scaling monitored/recurring revenue, and continuing to convert R&D into commercial outcomes. Management continues to evaluate capital markets options but is prioritizing business execution.
